Drug intelligence / Profile preview

crotamine

Development stage
Preclinical
Lead developer
Celtic Biotech
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
Oral, Intradermal
01

Overview

Crotamine is a 42–amino acid, highly basic, myotoxic and neurotoxic polypeptide isolated from the venom of the South American rattlesnake Crotalus durissus terrificus, best characterized as a cell-penetrating peptide with selective tropism for actively proliferating cells, including tumor cells.[1][2][5][9] It interacts with voltage-sensitive sodium channels and selectively inhibits Kv1.3 potassium channels, disrupts mitochondrial and lysosomal function, and perturbs intracellular calcium homeostasis, leading to myonecrosis and cytotoxicity.[1][2][5][9] Beyond its native toxic role, crotamine exhibits antimicrobial and antifungal activity, promotes insulin release, modulates inflammatory and angiogenic pathways, and has been shown in rodents to induce browning of white adipose tissue, increase basal energy expenditure, reduce weight gain, and improve glucose homeostasis after oral administration.[1][7][8] Because of its strong cell-penetrating and nucleolar-targeting properties, crotamine is being explored preclinically as a delivery vector for nucleic acids and other biomolecules, as an imaging tool for detecting dividing cells, and as a prototype for anticancer and metabolic-disorder drug design.[2][9][10][11]

Other names
rattlesnake toxin crotaminecrotalus durissus terrificus venom crotaminecell-penetrating peptide crotamine
02

Targets

PS (Phosphatidylserine)Sucrase-IsomaltaseKCNA3 (Potassium voltage-gated channel subfamily A member 3)GLP1R (GLP-1R)DPP-4 (Dipeptidyl Peptidase-IV)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on crotamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on crotamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call